An experimental mRNA cancer vaccine developed by Merck and Moderna has shown promising results in reducing the risk of melanoma recurrence, according to a new clinical trial.
The trial results indicate that the vaccine helps lower the chances of melanoma tumors returning, offering hope for patients who have undergone treatment for this type of skin cancer.
The findings were reported just hours ago, marking a significant development in the field of cancer immunotherapy. The collaboration between Merck and Moderna highlights the growing role of mRNA technology in fighting cancer.